2025-02-15 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Review

**0. Executive Summary:**

Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases.  The company significantly outperformed the S&P 500 (VOO) over the period analyzed, exhibiting higher growth and potentially higher risk.  Recent financial data shows strong revenue and profitability, but some quarter-to-quarter volatility exists.


**1. Performance Comparison & Alpha/Beta Analysis:**

Vertex Pharmaceuticals (VRTX) demonstrated a cumulative return of 159.53%, significantly outpacing the S&P 500's (VOO) cumulative return of 121.84%.  This represents a difference of 37.7%, placing it in the 64.9th percentile of its historical range relative to the S&P 500 (based on a minimum difference of -65.6% and a maximum of 93.5%).

The provided Alpha/Beta analysis reveals consistently positive alpha (outperformance relative to the market)  in most periods, ranging from 0.1 to 0.6, indicating consistent outperformance of the market. Beta values fluctuate, suggesting varying sensitivity to market movements, but generally remaining above 0.1.  The significant negative alpha of -80% during 2019-2021 is noteworthy and should be investigated further.  Market capitalization (Cap(B)) has steadily grown over the period.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 48.0% | 21.7% | 19.0% | 0.1 | 38.5 |
| 2016-2018  | 66.0% | 11.0% | 47.0% | 0.1 | 42.5 |
| 2017-2019  | 88.0% | 11.0% | 57.0% | 0.6 | 56.2 |
| 2018-2020  | 17.0% | 22.8% | -10.0% | 0.2 | 60.7 |
| 2019-2021  | -9.0% | 22.8% | -80.0% | 0.2 | 56.4 |
| 2020-2022  | 10.0% | 22.8% | 2.0% | 0.2 | 74.2 |
| 2021-2023  | 84.0% | 9.6% | 60.0% | 0.5 | 104.5 |
| 2022-2024  | 64.0% | 13.7% | 31.0% | 0.5 | 103.4 |
| 2023-2025  | 51.0% | 13.7% | -11.0% | 0.5 | 117.9 |


**2. Recent Price Movement:**

* **Closing Price:** $459.0
* **5-Day Moving Average:** $459.99
* **20-Day Moving Average:** $453.75
* **60-Day Moving Average:** $442.95

The price is slightly below the 5-day moving average, suggesting minor near-term downward pressure. However, it's above both the 20-day and 60-day moving averages, indicating a generally positive longer-term trend. The recent price change (-$0.77) represents a small decline.


**3. Technical Indicators & Expected Return:**

* **RSI:** 57.09 (Slightly below neutral; neither overbought nor oversold)
* **PPO:** -0.13 (Negative, suggesting bearish momentum)
* **Relative Strength Change (20-day):** -5.8% (Short-term weakening)
* **Expected Return (Long-term, >2 years):** 21.2% (Significant outperformance relative to the S&P 500)

The recent small price drop, coupled with a negative PPO and declining relative strength, hints at potential short-term bearishness.  However, the long-term expected return remains positive and substantial.


**4. Recent Earnings Analysis:**

The earnings data shows significant volatility.  There's a large negative EPS in August 2024 (-$13.92) that drastically contrasts with positive EPS in other quarters. Revenue has been relatively consistent, showing a slight upward trend.  Further investigation is needed to understand the cause of the outlier EPS figure.

| 날짜       | EPS    | 매출        |
|------------|--------|-------------|
| 2024-11-05 | 4.05   | 2.77 B$     |
| 2024-08-02 | -13.92 | 2.65 B$     |
| 2024-05-07 | 4.26   | 2.69 B$     |
| 2023-11-07 | 4.01   | 2.48 B$     |
| 2024-11-05 | 4.01   | 2.48 B$     |  *(Note: Duplicate entry - likely a data error)*


**5. Financial Information:**

Revenue remains strong and consistently high, with profit margins consistently above 85%.  However, the Equity and ROE data reveals volatility, with a significant negative ROE in Q2 2024 (-24.32%). This requires further investigation to understand the underlying causes.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.91B | 85.46% |
| 2024-09-30 | $2.77B | 85.84% |
| 2024-06-30 | $2.65B | 85.94% |
| 2024-03-31 | $2.69B | 87.27% |
| 2023-12-31 | $2.52B | 85.38% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $16.41B | 5.56% |
| 2024-09-30 | $15.63B | 6.69% |
| 2024-06-30 | $14.77B | -24.32% |
| 2024-03-31 | $18.55B | 5.93% |
| 2023-12-31 | $17.58B | 5.51% |


**6. Overall Analysis:**

VRTX has shown a strong track record of outperformance compared to the S&P 500, supported by generally positive alpha and a consistently high revenue and profit margin.  However, recent data reveals some volatility, particularly in earnings and ROE.  The significant negative EPS in Q2 2024 and the negative ROE for the same period require deeper analysis to determine the underlying causes.  While the long-term outlook appears promising based on the high expected return, investors should carefully consider the observed volatility and conduct further due diligence before making investment decisions.  The significant negative alpha (-80%) during 2019-2021 warrants specific investigation to understand the contributing factors and assess the risk of recurrence.
